克拉霉素潛在不良藥物相互作用分析及精細(xì)化前置審方規(guī)則建立

中圖分類號(hào)R969.2 文獻(xiàn)標(biāo)志碼A 文章編號(hào) 1001-0408（2025）08-0986-05

DOI 10.6039/j.issn.1001-0408.2025.08.17

Analysis clarithromycin potential adverse drug interactions and establishment refined prescription pre-reviewrules

WANG Long'，ZHANG ， ZHU Lingna'， ZHANG Guanjun'，CHENG Jun'（1. Pharmacy， the ， Anhui 233099， China； 2. Pharmacy， the Second ，China）

ABSTRACTOBJECTIVEToanalyzethepotentialadverse druginteractions（pADIs） clarithromycinand establish refined prescriptionpre-reviewrules.METHODSOutpatient prescriptionsclarithromycinincombinationwithotherdrugswerecolleced fromJanuary1，024toJune302024throughhospitalinfomationsystemthepADswere identifiedandtheirrisksevertiesweregradedaccording toLexicompandMicromedexdatabases.Then，refinedprescriptionprereviw rulesforclarthromycinpADIs-relateddrugs wereestablishedaccrding totheidentificationandrisklevelresults. RESULTS Among 3046clarithromycincombineddrug prescriptions，946cases pADIsoccured in 812 prescriptions.There were6，415and525casesclasifiedas“contraindicated"，“major"and“moderate"”，respectively.Thecombinationdrugs with “contraindicated"levels weretamsulosin，rupatadine，domperidoneandticagrelor，whilethose with“major"levels were mainly theophylline，dexamethasoneandamlodipine.Accordingly，26refinedrules wereestablished，including4items“warning information→prescriptioninterception"，1litems“waming information→prescriptiondoublesignature"and1litems “atention information→prescriptionapproval".CONCLUSIONS There are“contraindicated"and“major"risks asociated with clarithromycinanditscombinatindrugsinthehospitalandrefinedpresciptionpre-reviewrulesforclarithromycincombineddrug prescription have been established successfully.

EYWORDS clarithromycin； potential adverse drug interactions； prescription pre-reviev

克拉霉素是一種半合成14元環(huán)的紅霉素衍生物，屬于第二代大環(huán)內(nèi)酯類抗菌藥物，具有半衰期長、對(duì)酸穩(wěn)定、生物利用度高和患者耐受性好等特點(diǎn)；該藥對(duì)革蘭氏陽性菌、厭氧菌、支原體及衣原體等均有抗菌活性，已廣泛用于治療支氣管炎、肺炎、百日咳、咽炎、鼻竇炎、毛囊炎和幽門螺桿菌感染等疾病-2]。（剩余8733字）